Ahmedabad-based Uniza Group has entered into an exclusive tie-up with Lysulin - an innovator company from the US to launch Lysulin - a breakthrough evidence-based nutritional product for Indian Market. Lysulin is patented in the USA for the prevention of protein glycation using Lysine supplements and as a method of diabetes support using a supplement.

UNIZA is a pharmaceutical venture of Pashupati Group. The company has set up a modern, state-of-the-art facility complying with WHO-GMP and PIC/S guidelines at Kadi near Ahmedabad, Gujarat. Having launched India business in August 2020, the company has gradually expanded its product range to over 80 SKU’s with a sale of Rs 25 crore in the first year.

Sreekanth Seshadri, CEO and Managing Partner, Uniza Healthcare, said, "We endeavour to bring the best of global healthcare products to India and the launch of Lysulin, Schones and Keratizaare testimony to our commitment. The company is looking to introduce more innovative products in India. Focussed on dermatology, cardiology and diabetes management we offer products that include antifungals, anti-dandruff preparations, moisturizers, antibiotics, anti-allergic preparations, anti-acne, multi-vitamins, anti-hypertensives, oral hypoglycemic agents, lipid-lowering agents and iron preparations."

"Our international business would mainly focus on ROW markets like Africa, LATAM, South East Asia and CIS countries and planning to file over 180 dossiers. Our Indian business is aiming to achieve sales of Rs 100 crore in FY 2021-22," said Saurin Parikh, MD, Uniza Group & Founder, Pashupati Group.